Roald Anca B, Aass Hans C D, Moe Morten C
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
Br J Ophthalmol. 2015 Dec;99(12):1610-3. doi: 10.1136/bjophthalmol-2015-306781. Epub 2015 May 12.
To provide data on plasma vascular endothelial growth factor (VEGF) concentration during three consecutive monthly intravitreal aflibercept injections and after transition to bimonthly treatment in patients with neovascular age-related macular degeneration (nAMD).
Sixteen consecutive treatment-naïve Caucasian patients with nAMD were included in the study. The treatment consisted of one intravitreal aflibercept (2 mg) injection every 28 days for three consecutive months followed by a fourth injection 8 weeks later. VEGF plasma concentrations were measured with Luminex on day 0 (baseline, prior to first injection); days 1, 6 and 27 (prior to second injection); day 55 (prior to third injection) and days 97 and 111 (after third injection).
Baseline plasma VEGF concentration was 59.6±13.3 pg/mL. Aflibercept decreased plasma VEGF concentration to 32.5±3 pg/mL on day 1 (p<0.0001) and 34.7±6.3 pg/mL on day 6 (p<0.0001). On day 27, the VEGF plasma level increased to 50.6±6.5 pg/mL (p=0.009) and on day 55 to 52.8±8.8 pg/mL (p=0.027). There was no statistically significant difference between mean plasma VEGF concentrations on days 27 and 55 (p=0.139). Plasma VEGF concentration recovered completely 6 weeks after the third injection, reaching 57.9±9.6 pg/mL on day 97 (p=0.600) and 59.5±11.6 pg/mL on day 111 (p=0.987).
Intravitreal aflibercept decreases plasma VEGF concentration mostly in the first week after treatment. Despite repeated monthly intravitreal injections, there was a monthly increase in plasma VEGF values to near baseline levels, with complete recovery 6 weeks after the third injection.
Identifier no. NCT02125864.
提供新生血管性年龄相关性黄斑变性（nAMD）患者连续三个月每月一次玻璃体内注射阿柏西普期间以及转为每两个月治疗一次后的血浆血管内皮生长因子（VEGF）浓度数据。
16例初治的白种人nAMD患者纳入本研究。治疗方案为每28天玻璃体内注射一次阿柏西普（2mg），连续三个月，随后在8周后进行第四次注射。在第0天（基线，首次注射前）、第1天、第6天和第27天（第二次注射前）、第55天（第三次注射前）以及第97天和第111天（第三次注射后）用Luminex检测血浆VEGF浓度。
基线血浆VEGF浓度为59.6±13.3pg/mL。阿柏西普在第1天将血浆VEGF浓度降至32.5±3pg/mL（p<0.0001），在第6天降至34.7±6.3pg/mL（p<0.0001）。在第27天，VEGF血浆水平升至50.6±6.5pg/mL（p=0.009），在第55天升至52.8±8.8pg/mL（p=0.027）。第27天和第55天的平均血浆VEGF浓度之间无统计学显著差异（p=0.139）。第三次注射6周后血浆VEGF浓度完全恢复，第97天达到57.9±9.6pg/mL（p=0.600），第111天达到59.5±11.6pg/mL（p=0.987）。
玻璃体内注射阿柏西普主要在治疗后的第一周降低血浆VEGF浓度。尽管每月重复进行玻璃体内注射，但血浆VEGF值每月仍会升高至接近基线水平，第三次注射6周后完全恢复。
标识符编号NCT02125864。
